{
    "ticker": "PRQR",
    "name": "ProQR Therapeutics N.V.",
    "description": "ProQR Therapeutics N.V. is a biotechnology company focused on developing transformative medicines for the treatment of genetic diseases. Founded in 2014 and headquartered in Leiden, Netherlands, ProQR is dedicated to advancing RNA-based therapies that address the underlying causes of genetic disorders. The company's innovative approach involves utilizing its proprietary RNA editing technology to target and modify the RNA of patients, thereby potentially correcting mutations at the molecular level. ProQR's lead product candidates are aimed at treating rare diseases, including Leber's Congenital Amaurosis (LCA) and Usher Syndrome, which are caused by specific genetic mutations. By leveraging its deep expertise in RNA biology, the company is at the forefront of precision medicine, working to develop therapies that could significantly improve patients' quality of life. ProQR is committed to collaboration with the scientific community, patients, and advocacy groups to accelerate the development of its therapeutic candidates. The company's mission is to create a brighter future for patients suffering from genetic diseases, and it continues to explore new avenues in RNA therapeutics to expand its pipeline and reach.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Leiden, Netherlands",
    "founded": "2014",
    "website": "https://www.proqr.com",
    "ceo": "Daniel de Boer",
    "social_media": {
        "twitter": "https://twitter.com/ProQR",
        "linkedin": "https://www.linkedin.com/company/proqr-therapeutics/"
    },
    "investor_relations": "https://investors.proqr.com",
    "key_executives": [
        {
            "name": "Daniel de Boer",
            "position": "CEO"
        },
        {
            "name": "Evelyn K. N. H. van der Kooij",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "QR-110",
                "QR-112"
            ]
        }
    ],
    "seo": {
        "meta_title": "ProQR Therapeutics N.V. | Innovating RNA-Based Medicines",
        "meta_description": "Learn about ProQR Therapeutics N.V., a leader in RNA-based therapies for genetic diseases. Discover our innovative approach and pipeline of transformative medicines.",
        "keywords": [
            "ProQR",
            "Biotechnology",
            "RNA Therapy",
            "Genetic Diseases",
            "Leber's Congenital Amaurosis",
            "Usher Syndrome"
        ]
    },
    "faq": [
        {
            "question": "What is ProQR Therapeutics focused on?",
            "answer": "ProQR Therapeutics is focused on developing RNA-based medicines for genetic diseases."
        },
        {
            "question": "Who is the CEO of ProQR?",
            "answer": "Daniel de Boer is the CEO of ProQR Therapeutics N.V."
        },
        {
            "question": "Where is ProQR headquartered?",
            "answer": "ProQR is headquartered in Leiden, Netherlands."
        },
        {
            "question": "What are ProQR's main product candidates?",
            "answer": "ProQR's main product candidates include QR-110 and QR-112, targeting genetic disorders."
        },
        {
            "question": "When was ProQR founded?",
            "answer": "ProQR was founded in 2014."
        }
    ],
    "competitors": [
        "EDIT",
        "CRSP",
        "SGEN",
        "BMY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}